23
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Anemia-Inducing Substance Is Related to Elimination of Lipolytic Hyperactivity by Cyclic Plasma Perfusion in Human Cancer Cachexia

Pages 169-172 | Published online: 18 Nov 2009
 

Abstract

We previously reported that cyclic plasma perfusion suppressed lipolytic activity in malignant tumor-bearing animals and reversed their body weight loss. In this study we investigated the relation between this phenomenon and interleukin (IL) -1α, IL-1β, IL-6, interferon-γ, leukemia inhibitory factor, tumor necrosis factor-α, and anemia-inducing substance (AIS) in vitro by examining changes in their levels in the plasma of advanced ovarian cancer patients. When the patients' plasma was incubated with noncoated charcoal for one hour, its lipolytic activity decreased by 39.0 ± 2.4%, which was similar to the results obtained with the plasma of healthy subjects. IL-1a, IL-1β, interferon-g, leukemia inhibitory factor, and tumor necrosis factor-α did not adsorb the charcoal. IL-6 was 3.7% adsorbed, but this did not cause a significant difference (p = 0.131). Nor was the recombinant form of these cytokines adsorbed to the charcoal. AIS, however, was 98.1% adsorbed. These results indicate that AIS is strongly associated with the reduction in lipolytic activity by cyclic plasma perfusion through noncoated charcoal resin.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.